Nano-encapsulated Tryptanthrin Derivative for Combined Anticancer Therapy Via Inhibiting Indoleamine 2,3-Dioxygenase and Inducing Immunogenic Cell Death.

Canyu Yang,Bing He,Qiang Zheng,Dakuan Wang,Mengmeng Qin,Hua Zhang,Wenbing Dai,Qiang Zhang,Xiangbao Meng,Xueqing Wang
DOI: https://doi.org/10.2217/nnm-2019-0074
2019-01-01
Nanomedicine
Abstract:Aim: We developed a polycaprolactone-based nanoparticle (NP) to encapsulate tryptanthrin derivative CY-1-4 and evaluated its antitumor efficacy. Materials & methods: CY-1-4 NPs were prepared and evaluated for their cytotoxicity and associated mechanisms, indoleamine 2,3-dioxygenase (IDO)-inhibitory ability, immunogenic cell death (ICD)-inducing ability and antitumor efficacy. Results: CY-1-4 NPs were 123 nm in size. In vitro experiments indicated that they could both induce ICD and inhibit IDO. In vivo studies indicated that a medium dose reduced 58% of the tumor burden in a B16-F10-bearing mouse model, decreased IDO expression in tumor tissues and regulated lymphocytes subsets in spleen and tumors. Conclusion: CY-1-4 is a potential antitumor candidate that could act as a single agent with combined functions of IDO inhibition and ICD induction.
What problem does this paper attempt to address?